101 related articles for article (PubMed ID: 16314195)
1. Elevation of hyaluronidase-1 and soluble intercellular adhesion molecule-1 helps select bladder cancer patients at risk of invasion.
Aboughalia AH
Arch Med Res; 2006 Jan; 37(1):109-16. PubMed ID: 16314195
[TBL] [Abstract][Full Text] [Related]
2. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
Colombo R
Eur Urol; 2010 Jan; 57(1):93-4. PubMed ID: 19345471
[No Abstract] [Full Text] [Related]
4. Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages.
Coskun U; Sancak B; Sen I; Bukan N; Tufan MA; Gülbahar O; Sozen S
Int Immunopharmacol; 2006 Apr; 6(4):672-7. PubMed ID: 16504931
[TBL] [Abstract][Full Text] [Related]
5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of clusterin expression to prognosis of bladder carcinoma].
Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL
Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
10. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
12. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.
Fong A; Garcia E; Gwynn L; Lisanti MP; Fazzari MJ; Li M
Am J Clin Pathol; 2003 Jul; 120(1):93-100. PubMed ID: 12866378
[TBL] [Abstract][Full Text] [Related]
13. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
Ma Y; Hou Y; Liu B; Li X; Yang S; Ma J
Anat Rec (Hoboken); 2010 Nov; 293(11):1847-54. PubMed ID: 20730866
[TBL] [Abstract][Full Text] [Related]
15. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma.
Pagano F; Garbeglio A; Milani C; Bassi P; Pegoraro V
Eur Urol; 1987; 13(3):145-9. PubMed ID: 3609087
[TBL] [Abstract][Full Text] [Related]
20. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion.
Eiján AM; Sandes EO; Riveros MD; Thompson S; Pasik L; Mallagrino H; Celeste F; Casabé AR
Cancer; 2003 Jul; 98(2):262-8. PubMed ID: 12872343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
